サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1753970

医薬品連続製造市場レポート：治療タイプ別、製剤別、用途別、エンドユーザー別、地域別、2025年～2033年

Pharmaceutical Continuous Manufacturing Market Report by Therapeutics Type, Formulation, Application, End User, and Region 2025-2033

出版日
発行
IMARC
ページ情報
英文 150 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.80円
医薬品連続製造市場レポート：治療タイプ別、製剤別、用途別、エンドユーザー別、地域別、2025年～2033年
出版日: 2025年06月02日
発行: IMARC
ページ情報: 英文 150 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の医薬品連続製造市場規模は2024年に15億米ドルに達しました。今後、IMARC Groupは、市場は2033年までに33億米ドルに達し、2025年から2033年にかけて9.62%の成長率（CAGR）を示すと予測しています。健康への関心の高まりと研究開発活動の活発化が市場の成長を後押ししています。

医薬品連続製造市場分析：

  • 主な市場促進要因：製品品質の向上、汚染リスクの低減、製造工程のリアルタイムモニタリングの可能性から、規制機関は連続製造を支持しています。
  • 主な市場動向：効果的な医薬品製造システムに対する需要の高まりが、市場成長にプラスの影響を与えています。
  • 競合情勢：市場の著名企業には、Baker Perkins、Coperion GmbH（Hillenbrand Inc.）、Eli Lilly and Company、GEA Group Aktiengesellschaft、Glatt GmbH、Korsch AG、Novartis AG、Siemens、SK biotek、Thermo Fisher Scientific Inc.、Viatris Inc.などがあります。
  • 地理的動向：北米は、その高度な技術インフラにより、市場において明確な優位性を示しています。これとは別に、この地域の高度に熟練した労働力と強力な規制支援が市場の成長を加速させています。
  • 課題と機会：システムの高コストが市場の妨げとなっています。しかし、業界の協力とリソースの共有がコストと知識の分散に役立ち、市場の成長を強化しています。

医薬品連続製造市場動向：

ドラッグデリバリーシステムの革新

先端材料、プロセス分析技術（PAT）、標的ナノメディシンのようなドラッグデリバリーシステムにおける現代の進歩は、標的への送達、安定性、リアルタイムモニタリング、溶解性を改善した薬剤の連続生産ラインを可能にします。これらの要因が相まって、市場は加速しています。例えば、国立医学図書館が2024年5月に発表した論文では、リポソームや脂質ナノ粒子（LNP）などの技術や、スマート、キャリアベース、3Dプリントによるドラッグデリバリー法の開発に注力することで、バイオアベイラビリティが向上し、従来の限界に対処し、研究が進むと述べられています。

製造工程における規制支援

規制機関は、製品の一貫性や効率性の向上など、連続製造の利点を認めるようになってきています。これらの機関は、連続製造技術を導入するための明確な基準と規制上の道筋を示す包括的なガイドラインとプログラムを確立しました。例えば、米国食品医薬品局（FDA）は2024年5月、希少疾患治療薬の開発を促進するためのSTARTパイロットプログラムを開始しました。これは臨床試験支援と規制ガイダンスに重点を置いたもので、新製品開発の加速と生産要件の最適化によって連続製造に利益をもたらし、医薬品連続製造市場統計を増加させています。

慢性疾患の発生率の増加

心血管疾患、糖尿病、慢性呼吸器疾患などの慢性疾患が蔓延するにつれ、信頼性の高い長期的な治療に対する需要が高まっています。連続製造プロセスは、効率性と一貫した品質で高品質の医薬品を大規模に製造できるため、この需要に対応できます。これに伴い、医薬品連続製造の価格動向の採用により、製造コストと無駄が削減され、治療がより手頃な価格で受けられるようになります。例えば、2024年2月にPublic Health Researchが発表した調査によると、米国では約1億2,900万人が少なくとも1つの主要な慢性疾患を抱えています。

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 世界の医薬品連続製造市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：治療タイプ別

  • ラージモレキュール
  • スモールモレキュール

第7章 市場内訳：製剤別

  • 固形製剤
  • 液体・半固体製剤

第8章 市場内訳：用途別

  • 最終医薬品製造
  • API製造

第9章 市場内訳：エンドユーザー別

  • 製薬企業
  • CMO
  • その他

第10章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋地域
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場内訳：国別

第11章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第14章 価格分析

第15章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Baker Perkins
    • Coperion GmbH（Hillenbrand Inc.）
    • Eli Lilly and Company
    • GEA Group Aktiengesellschaft
    • Glatt GmbH
    • Korsch AG
    • Novartis AG
    • Siemens
    • SK biotek
    • Thermo Fisher Scientific Inc.
    • Viatris Inc.
図表

List of Figures

  • Figure 1: Global: Pharmaceutical Continuous Manufacturing Market: Major Drivers and Challenges
  • Figure 2: Global: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Pharmaceutical Continuous Manufacturing Market: Breakup by Therapeutics Type (in %), 2024
  • Figure 5: Global: Pharmaceutical Continuous Manufacturing Market: Breakup by Formulation (in %), 2024
  • Figure 6: Global: Pharmaceutical Continuous Manufacturing Market: Breakup by Application (in %), 2024
  • Figure 7: Global: Pharmaceutical Continuous Manufacturing Market: Breakup by End User (in %), 2024
  • Figure 8: Global: Pharmaceutical Continuous Manufacturing Market: Breakup by Region (in %), 2024
  • Figure 9: Global: Pharmaceutical Continuous Manufacturing (Large Molecules) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 10: Global: Pharmaceutical Continuous Manufacturing (Large Molecules) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 11: Global: Pharmaceutical Continuous Manufacturing (Small Molecules) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 12: Global: Pharmaceutical Continuous Manufacturing (Small Molecules) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 13: Global: Pharmaceutical Continuous Manufacturing (Solid Formulation) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 14: Global: Pharmaceutical Continuous Manufacturing (Solid Formulation) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 15: Global: Pharmaceutical Continuous Manufacturing (Liquid and Semi-solid Formulation) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 16: Global: Pharmaceutical Continuous Manufacturing (Liquid and Semi-solid Formulation) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 17: Global: Pharmaceutical Continuous Manufacturing (Final Drug Product Manufacturing) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 18: Global: Pharmaceutical Continuous Manufacturing (Final Drug Product Manufacturing) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 19: Global: Pharmaceutical Continuous Manufacturing (API Manufacturing) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 20: Global: Pharmaceutical Continuous Manufacturing (API Manufacturing) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 21: Global: Pharmaceutical Continuous Manufacturing (Pharmaceutical Companies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 22: Global: Pharmaceutical Continuous Manufacturing (Pharmaceutical Companies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 23: Global: Pharmaceutical Continuous Manufacturing (Contract Manufacturing Organizations) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 24: Global: Pharmaceutical Continuous Manufacturing (Contract Manufacturing Organizations) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 25: Global: Pharmaceutical Continuous Manufacturing (Others) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 26: Global: Pharmaceutical Continuous Manufacturing (Others) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 27: North America: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 28: North America: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 29: United States: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 30: United States: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 31: Canada: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 32: Canada: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 33: Asia-Pacific: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 34: Asia-Pacific: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 35: China: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 36: China: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 37: Japan: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 38: Japan: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 39: India: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 40: India: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 41: South Korea: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 42: South Korea: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 43: Australia: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 44: Australia: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 45: Indonesia: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 46: Indonesia: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 47: Others: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 48: Others: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 49: Europe: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 50: Europe: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 51: Germany: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 52: Germany: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 53: France: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 54: France: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 55: United Kingdom: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 56: United Kingdom: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 57: Italy: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 58: Italy: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 59: Spain: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 60: Spain: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 61: Russia: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 62: Russia: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 63: Others: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 64: Others: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 65: Latin America: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 66: Latin America: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 67: Brazil: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 68: Brazil: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 69: Mexico: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 70: Mexico: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 71: Others: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 72: Others: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 73: Middle East and Africa: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 74: Middle East and Africa: Pharmaceutical Continuous Manufacturing Market: Breakup by Country (in %), 2024
  • Figure 75: Middle East and Africa: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 76: Global: Pharmaceutical Continuous Manufacturing Industry: SWOT Analysis
  • Figure 77: Global: Pharmaceutical Continuous Manufacturing Industry: Value Chain Analysis
  • Figure 78: Global: Pharmaceutical Continuous Manufacturing Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Pharmaceutical Continuous Manufacturing Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Pharmaceutical Continuous Manufacturing Market Forecast: Breakup by Therapeutics Type (in Million USD), 2025-2033
  • Table 3: Global: Pharmaceutical Continuous Manufacturing Market Forecast: Breakup by Formulation (in Million USD), 2025-2033
  • Table 4: Global: Pharmaceutical Continuous Manufacturing Market Forecast: Breakup by Application (in Million USD), 2025-2033
  • Table 5: Global: Pharmaceutical Continuous Manufacturing Market Forecast: Breakup by End User (in Million USD), 2025-2033
  • Table 6: Global: Pharmaceutical Continuous Manufacturing Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 7: Global: Pharmaceutical Continuous Manufacturing Market: Competitive Structure
  • Table 8: Global: Pharmaceutical Continuous Manufacturing Market: Key Players
目次
Product Code: SR112025A5935

The global pharmaceutical continuous manufacturing market size reached USD 1.5 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 3.3 Billion by 2033, exhibiting a growth rate (CAGR) of 9.62% during 2025-2033. The rising health concerns and the increasing research and development activities are propelling the market growth.

Pharmaceutical Continuous Manufacturing Market Analysis:

  • Major Market Drivers: Regulatory agencies are supportive of continuous manufacturing due to its potential to enhance product quality, reduce contamination risks, and provide real-time monitoring of the production process.
  • Key Market Trends: The rising demand for effective medicine production systems is positively impacting the market growth.
  • Competitive Landscape: Some of the prominent companies in the market include Baker Perkins, Coperion GmbH (Hillenbrand Inc.), Eli Lilly and Company, GEA Group Aktiengesellschaft, Glatt GmbH, Korsch AG, Novartis AG, Siemens, SK biotek, Thermo Fisher Scientific Inc., and Viatris Inc., among many others.
  • Geographical Trends: North America exhibits a clear dominance in the market due to its advanced technological infrastructure. Apart from this, the region's highly skilled workforce and strong regulatory support accelerate the market growth.
  • Challenges and Opportunities: The high cost of systems is hindering the market. However, industry collaborations and shared resources help in distributing the cost and knowledge, which strengthens the market growth.

Pharmaceutical Continuous Manufacturing Market Trends:

Innovation in Drug Delivery System

Modern advances in drug delivery systems, like advanced materials, process analytical technology (PAT), and targeted nanomedicine, enable continuous production lines to produce drugs with improved targeted delivery, stability, real-time monitoring, and solubility. Collectively, these factors accelerate the market. For instance, an article published by the National Library of Medicine in May 2024 mentioned that focusing on technologies, such as liposomes and lipid nanoparticles (LNPs) and development in smart, carrier-based, and 3D-printed drug delivery methods improve bioavailability, address conventional limitations, and advance research.

Regulatory Support in Manufacturing Process

Regulatory bodies have increasingly acknowledged the benefits of continuous manufacturing, like product consistency and enhanced efficiency. These agencies established comprehensive guidelines and programs that provide clear standards and regulatory pathways for implementing continuous manufacturing technologies. For instance, in May 2024, the U.S. Food and Drug Administration (FDA) launched the START pilot program to accelerate the development of rare disease therapeutics. It focuses on clinical trial support and regulatory guidance, which benefits continuous manufacturing by accelerating novel product development and optimizing production requirements, which is increasing the pharmaceutical continuous manufacturing market statistics.

Increasing Incidence of Chronic Disease

As chronic conditions such as cardiovascular diseases, diabetes, and chronic respiratory diseases become more prevalent, there is an increased demand for reliable and long-term treatments. Continuous manufacturing processes meet this demand due to their ability to produce quality pharmaceuticals at scale with efficiency and consistent quality. In line with this, the adoption of pharmaceutical continuous manufacturing price trends reduces production costs and waste, thereby making treatments more affordable and accessible. For example, research published by Public Health Research in February 2024 showed that approximately 129 million people in the United States have at least one major chronic disease.

Global Pharmaceutical Continuous Manufacturing Industry Segmentation:

Breakup by Therapeutics Type:

  • Large Molecules
  • Small Molecules

Small molecules dominate the pharmaceutical continuous manufacturing market

Continuous manufacturing enhances efficiency and consistency in small-molecule drugs. Vertex Pharmaceuticals introduced Suzetrigine, a small molecule drug manufactured using continuous processes, optimizing production efficiency and ensuring consistent quality for pain management.

Breakup by Formulation:

  • Solid Formulation
  • Liquid and Semi-solid Formulation

Solid formulation currently holds most of the pharmaceutical continuous manufacturing market demand

Solid formulations, such as capsules and tablets, excel in continuous manufacturing due to improved consistency and efficiency. For example, XenoPharma's tablet production ensures uniform quality and scalable output, which is acting as another significant growth-inducing factor.

Breakup by Application:

  • Final Drug Product Manufacturing
  • API Manufacturing

Final drug product manufacturing dominates the market

Final drug product manufacturing in continuous processes ensures efficient production with consistent quality and scalability, thereby reducing waste and enhancing overall process control. It also results in cost savings. This is bolstering the pharmaceutical continuous manufacturing market revenue.

Breakup by End User:

  • Pharmaceutical Companies
  • Contract Manufacturing Organizations
  • Others

Pharmaceutical companies hold most of the pharmaceutical continuous manufacturing market outlook

Pharmaceutical companies increasingly adopt continuous manufacturing to enhance efficiency, streamline production processes, and ensure consistent product quality. This is leading to faster and more cost-effective drug development.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America exhibits a clear dominance, accounting for the largest pharmaceutical continuous manufacturing market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

As per the pharmaceutical continuous manufacturing market research report, North America accounted for the largest share, driven by advanced drug delivery technologies. Moreover, regulatory bodies in the region are highly supportive of continuous manufacturing practices. The corporation with regulatory bodies encourages pharmaceutical companies to adopt continuous manufacturing solutions, thereby propelling the market growth. For instance, in May 2024, the U.S. Food and Drug Administration (FDA) introduced the START pilot program to catalyze the development of rare disease therapeutics.

Competitive Landscape:

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major market pharmaceutical continuous manufacturing companies have also been provided. Some of the key players in the market include:

  • Baker Perkins
  • Coperion GmbH (Hillenbrand Inc.)
  • Eli Lilly and Company
  • GEA Group Aktiengesellschaft
  • Glatt GmbH
  • Korsch AG
  • Novartis AG
  • Siemens
  • SK biotek
  • Thermo Fisher Scientific Inc.
  • Viatris Inc.

Key Questions Answered in This Report

  • 1.How big is the global pharmaceutical continuous manufacturing market?
  • 2.What is the expected growth rate of the global pharmaceutical continuous manufacturing market during 2025-2033?
  • 3.What are the key factors driving the global pharmaceutical continuous manufacturing market?
  • 4.What has been the impact of COVID-19 on the global pharmaceutical continuous manufacturing market growth?
  • 5.What is the breakup of the global pharmaceutical continuous manufacturing market based on the therapeutics type?
  • 6.What is the breakup of the global pharmaceutical continuous manufacturing market based on formulation?
  • 7.What is the breakup of the global pharmaceutical continuous manufacturing market based on the application?
  • 8.What is the breakup of the global pharmaceutical continuous manufacturing market based on the end user?
  • 9.What are the key regions in the global pharmaceutical continuous manufacturing market?
  • 10.Who are the key players/companies in the global pharmaceutical continuous manufacturing market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Pharmaceutical Continuous Manufacturing Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Therapeutics Type

  • 6.1 Large Molecules
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Small Molecules
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Formulation

  • 7.1 Solid Formulation
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Liquid and Semi-solid Formulation
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Final Drug Product Manufacturing
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 API Manufacturing
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Pharmaceutical Companies
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Contract Manufacturing Organizations
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Others
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Baker Perkins
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
    • 15.3.2 Coperion GmbH (Hillenbrand Inc.)
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
    • 15.3.3 Eli Lilly and Company
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 GEA Group Aktiengesellschaft
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 Glatt GmbH
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
    • 15.3.6 Korsch AG
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
    • 15.3.7 Novartis AG
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Siemens
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 SK biotek
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
    • 15.3.10 Thermo Fisher Scientific Inc.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Viatris Inc.
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials